| Full Name | Brooke Finch |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3258 Nidover Dr, Akron, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922705953 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brooke Finch, 150 N Miller Rd Ste 150a, Fairlawn, OH 44333-3713 Ph: () - | Brooke Finch, 3258 Nidover Dr, Akron, OH 44312-4628 Ph: (234) 867-8260 |
News Archive
The Juvenile Diabetes Research Foundation today announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease - the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.
The latest bird flu virus that killed a 39-year-old bus driver in the southern Chinese city of Shenzhen over the weekend is not yet transmissible between humans, Chinese health authorities said. The man, who lived in Shenzhen just across the border from Hong Kong, died from multi-organ failure on Saturday, a week after being admitted to hospital with a fever brought on by the virus, state media reported.
Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).
Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.
Stopping disruptions in cellular "trash removal" brought on by errors in molecular marks on DNA may guard against neurodegenerative diseases like Parkinson's.
› Verified 3 days ago
Michele Y Gunther, S.P.L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Jamie Blaylock, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 450 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-376-0153 | |
Kimberly Marie Gibbons, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2425 Foxboro Ave, Akron, OH 44305 Phone: 330-631-5678 | |
Kristin Weaver, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Mrs. Elizabeth Kinzig, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Wyant Rd, Akron, OH 44313 Phone: 330-836-7953 | |
Mrs. Andrea P. Brewer, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 181 Polsky Building, Akron, OH 44325 Phone: 330-972-8189 Fax: 330-972-7884 | |
Mary Mariani-walker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-873-3396 |